Balixafortide (a CXCR4 antagonist) plus eribulin in HER2-negative metastatic breast cancer (MBC): A Phase I open-label trial. (April 2018) - Kaufman, P.A.; Pernas, S.; Martin, M.; Gil-Martin, M.; Gomez Pardo, P.; Sara, L.T.; Manso, L.; Ciruelos, E.; Perez-Fidalgo, J.A.; Hernando, C.; Ademuyiwa, F.O.; Weilbaecher, K.; et al.